By integrating mechanistic insights with advanced therapeutic approaches, targeting the BDNF–ERK axis offers a realistic avenue not only for slowing neurodegeneration but also for potentially restoring neuronal function and improving quality of life in patients with Alzheimer’s, Parkinson’s, and Huntington’s disease. This evidence concerns the gene MAPK1 and juvenile Huntington disease.